APA

Moore C. S., Earl N., Frenette R., Styhler A., Mancini J. A., Nicholson D. W., Hebb A. L. O., Owens T. & Robertson G. S. (20061102). Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. : The Journal of pharmacology and experimental therapeutics.

Chicago

Moore C S, Earl N, Frenette R, Styhler A, Mancini J A, Nicholson D W, Hebb A L O, Owens T and Robertson G S. 20061102. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. : The Journal of pharmacology and experimental therapeutics.

Harvard

Moore C. S., Earl N., Frenette R., Styhler A., Mancini J. A., Nicholson D. W., Hebb A. L. O., Owens T. and Robertson G. S. (20061102). Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. : The Journal of pharmacology and experimental therapeutics.

MLA

Moore C S, Earl N, Frenette R, Styhler A, Mancini J A, Nicholson D W, Hebb A L O, Owens T and Robertson G S. Peripheral phosphodiesterase 4 inhibition produced by 4-[2-(3,4-Bis-difluoromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]-3-methylpyridine-1-oxide (L-826,141) prevents experimental autoimmune encephalomyelitis. : The Journal of pharmacology and experimental therapeutics. 20061102.